Over the past six months, Peptonic has worked closely with a a cutting-edge American marketing agency to develop a tailored brand platform and marketing initiatives that clearly position VagiVital in the segment of clinically proven intimate care in the U.S. In November, Peptonic will launch an extensive marketing campaign, featuring digital advertising and influencer collaborations on platforms such as Instagram, TikTok, and Google Ads. Leveraging digital channels offers a cost-effective way to reach a broad female audience, while also allowing campaigns to be quickly adjusted and retargeted based on performance. The campaign primarily aims to drive online sales through Peptonic's own webshop, but also through selected retailers.

"Our expansion in the U.S. marks a significant milestone in Peptonic's growth strategy. By taking full control of our marketing and sales, we can build a stronger brand presence and drive more targeted growth. Simultaneously, we're continuing discussions with major U.S. retail chains to expand their offerings with more of our intimate care products, which will continue to be sold under their own brands." Says Anna Linton, CEO of Peptonic Medical.

For further information, please contact:                                                                                        

Anna Linton, CEO Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone:  +46 70-244 92 07

About Peptonic

PEPTONIC medical AB (publ) is a cutting-edge Swedish biomedical company, dedicated in the development and distribution of clinically proven self-care treatments and self-diagnostic tests in intimate women's health. The portfolio is sold under the brands Vagivital and Vernivia.

The company's vision is to revolutionize intimate health by empowering women to diagnose, treat, and prevent intimate medical conditions independently and effectively. Intimate health shall be natural, safe, and easy for women to manage on their own.

Central to Peptonic's growth strategy is the geographical expansion of VagiVital and Vernivia through local partners. Peptonic Medical also intends to continuously broaden its product portfolio through acquisitions and the development of innovative and competitive products in-house. The company's mousse-based drug delivery technology, Venerol, and the gel base in VagiVital create favorable conditions for expanding the portfolio.

The company is headquartered in Stockholm, Sweden, and has subsidiaries Common Sense Marketing Inc in the USA and Peptonic Medical Ltd in Israel. Peptonic Medical was founded in 2009, and the company's shares have been listed on the Spotlight Stock Market since 2014.